NCT03220633已完成1 期
A Double-Blind, Placebo-Controlled, Phase I Study To Assess Safety, Tolerability And Pharmacokinetics Of Single/Multiple Ascending Doses Of ATB-346 Orally Administrated In Healthy Male And Female Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
研究概览
简要总结
A double-blind, placebo-controlled, phase I study to assess safety, tolerability and pharmacokinetics of single/multiple ascending doses of atb-346 orally administered in healthy male and female subjects.
详细描述
Single ascending doses of ATB-346 given to multiple cohorts followed by multiple ascending doses of ATB-346 given to multiple cohorts in order to assess its safety, tolerability, and pharmacokinetics. A single dose cohort was also conducted to assess the effect of food on the drug's characteristics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Availability for the entire study period
- •Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee
- •Healthy male or female subjects aged between 18 and 55 years, inclusive, at the time of informed consent
- •Body mass index (BMI) greater than or equal to 18.50 kg/m2 and below 30.00 kg/m2
- •Non- or ex-smokers. An ex-smoker is defined as someone who completely stopped smoking for at least six months before Day 1 of this study
- •Clinical laboratory values within the laboratory's stated normal range; if not within this range, these must be without any clinical significance
- •Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, general biochemistry, electrocardiogram [ECG], and urinalysis)
- •Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer
- •A female volunteer must meet one of the following criteria:
- •If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 28 days prior to the first drug administration, during the study and for at least 60 days after the last dose. An acceptable method of contraception includes one of the following:
- •Abstinence from heterosexual intercourse
- •Systemic contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
- •Intrauterine device (with or without hormones)
- •Condom with spermicide
- •If of non-childbearing potential - should be surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state (at least one year without menses)
- •A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must meet the following criterion:
- •Participant is inapt to procreate, defined as surgically sterile (i.e. has undergone a vasectomy, it must be at least 6 months since the surgery)
- •Participant agrees to use of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration. An acceptable method of contraception includes one of the following:
- •Abstinence from heterosexual intercourse.
- •Condom with spermicide.
排除标准
- •Females who are pregnant or breastfeeding
- •Seated pulse rate less than 50 Beats per Minute (bpm) or more than 100 bpm at screening
- •Seated blood pressure below 100/60 mmHg or higher than 140/90 mmHg at screening
- •History of significant hypersensitivity to naproxen, other non-steroidal anti-inflammatory agents, or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- •Presence of significant gastrointestinal, liver, or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs or know to potentiate or predispose to undesired effects
- •Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease
- •Suicidal tendency, history of/or disposition to seizures, state of confusion, clinically relevant psychiatric diseases
- •Presence of out-of-range cardiac interval (PR < 110 msec, PR > 200 msec, QRS < 60 msec, QRS >110 msec and QTc > 440 msec) on the screening ECG or other clinically significant ECG abnormalities
- •Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (>3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
- •Any clinically significant illness in the previous 28 days before Day 1 of this study
- •Use of any enzyme-modifying drugs, including strong inhibitors of CYP enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem, and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort) in the previous 28 days before Day 1 of this study
- •Any history of tuberculosis and/or prophylaxis for tuberculosis
- •Positive urine screening of alcohol and/or drugs of abuse
- •Positive results to HIV Ag/Ab Combo, Hepatitis B surface Antigen (HBsAg) or anti-Hepatitis C Virus (HCV) tests
- •Females who are pregnant according to a positive serum pregnancy test
- •Volunteers who took an Investigational Product (in another clinical trial) in the previous 28 days before Day 1 of this study or who have already participated in this clinical study
- •Volunteers who donated 50 mL or more of blood in the previous 28 days before Day 1 of this study
- •Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc) in the previous 56 days before Day 1 of this study.
研究组 & 干预措施
ATB-346
Experimental
Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of ATB-346.
干预措施: ATB-346 (Drug)
Placebo
Placebo Comparator
Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
时间窗: Within one week following single dose administration or within one week following the final dose after two weeks of treatment regimen
Serum chemistry and hematology laboratory measures
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of BSG005.Invasive Fungal InfectionsNCT04921254Biosergen AS72
已完成
1 期
Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.Healthy VolunteersNCT05628116PHARMENTERPRISES LLC38
已完成
1 期
Study to Assess Safety, Tolerability and Reactogenicity of Vaccine "UniFluVec" After Two Intranasal Administrations in Healthy VolunteersInfluenza ANCT04650971Pharmenterprises Biotech LLC60
已完成
1 期
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy VolunteersInfluenzaAcute Respiratory InfectionNCT03459391PHARMENTERPRISES LLC32
已完成
1 期
XC8 Safety, Tolerability and Pharmacokinetics in Healthy VolunteersAsthmaNCT03441815PHARMENTERPRISES LLC28